Roche's Breast Cancer Drug Doesn't Make UK Watchdog's Cut
The U.K.'s health care cost watchdog on Friday nixed Avastin's chances of becoming a first-line breast cancer treatment in the country, saying research doesn't prove Roche Holding AG's drug would lengthen...To view the full article, register now.
Already a subscriber? Click here to view full article